|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Datamonitor, May 2002
Introduction, The oncology market will show dramatic development in both overall size and variety of available therapies over the next decade, driven by the emergence of innovative drugs. Large pharmaceutical companies should consider focusing on the development or in-licensing of innovative therapies in order to maintain oncology market share over the long-term. The utilization or acquisition of biotechnology expertise will play a vital role in their strength within this market., , , Scope of this report, Analysis of the cancer market by drug class and key pharmaceuticals, Detailed description of ten major tumor types including epidemiology, unmet needs and current treatments, Pipeline analysis for these ten tumor types and detailed analysis of all drugs in phase III including forecast sales of key agents to 2010, Analysis of key pharmaceutical companies in the cancer market and emerging biotechnology players, , , Report Highlights, Datamonitor forecasts the overall cancer market to grow to $44,361m by 2010, with innovative drug launches being the key growth drivers. Three novel classes of innovative drugs, growth inhibitors, gene therapies and antisense therapies are expected to reach the market before 2006., Investment in the development of innovative drug classes will be essential for establishment of market share within the growing cancer market, but novel cytotoxic and hormonal therapies that act in synergy with innovative therapies will also yield strong returns., The market will favor treatments that offer the best toxicity profiles in addition to efficacy, in order to improve patient quality of life., , , Key reasons to buy this report, Understand the impact that the launch of novel drug classes will have on the market, Identify companies that are aggressively developing their oncology franchise and the biotechnology companies that could become major players, Evaluate the impact of changes in disease management, rising incidence, genericization of blockbusters and other market and environmental factors,
Customers who bought this item also bought
Drugs of Tomorrow: Cancer Overview
Drugs of Tomorrow 2001: Cancer Overview
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Drugs of Tomorrow 2002: Colorectal Cancer
Chinese Markets for Cancer Treatment Drugs
Drugs of Tomorrow 2001: Lung Cancer
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Market Dynamics 2001: Anti-Cancer Innovatives Series
|
|
|
|
